You are here

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Knee Osteoarthritis, Hip Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Osteoarthritis of the knee or hip based on American College of Rheumatology criteria
with a radiographic (X ray) confirmation (a Kellgren Lawrence x-ray grade of ≥2);

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Body mass index (BMI) of >39 kg/m2;

- Pregnancy or intent to become pregnant

- Planned surgical procedure during the duration of the study

- History of clinically significant cardiovascular, central nervous system or
psychiatric disease

- Previous exposure to exogenous NGF or to an anti NGF antibody;

- Use of biologics other than study medication, Live or live-attenuated intranasal
vaccines (eg, Flumist), are allowable exceptions

NCT00994890
Pfizer
Terminated
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now